Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Inmune Bio Inc
(NQ:
INMB
)
10.85
-0.32 (-2.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Inmune Bio Inc
< Previous
1
2
Next >
INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology
July 10, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
May 24, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives IND Clearance from FDA, Represents First Ever Natural Killer Immunotherapy Trial for a Particular Cancer
May 08, 2023
Via
Investor Brand Network
Exposures
Product Safety
What to Know About the Future of Cancer Treatment
January 31, 2023
Via
StatePoint Media
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
May 08, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
April 24, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
April 19, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
April 11, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
April 03, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
February 21, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
February 08, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
January 25, 2023
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease
December 22, 2022
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
December 08, 2022
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer
December 06, 2022
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
November 29, 2022
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease
November 14, 2022
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
October 26, 2022
From
INmune Bio, Inc.
Via
GlobeNewswire
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
October 19, 2022
From
INmune Bio, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.